Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Other: Sequence 2Other: Sequence 1Other: Sequence 5Other: Sequence 3Other: Sequence 4Other: Sequence 6
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT01332890
- Locations
- π°π·
ASAN Medical Center, University of Ulsan, Seoul, Korea, Republic of
Bioequivalence Study of Letrozole 2.5 mg Tablets
Not Applicable
Completed
- Conditions
- Healthy
- Interventions
- Drug: Peratra (Sequence 2)Drug: Peratra (Sequence 1)
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT01084499
Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: YH4808 400 mg (repeat doses)Drug: YH4808 600mgDrug: YH4808 50mgDrug: PlaceboDrug: YH4808 30mgDrug: YH4808 200mg (repeat dose)Drug: YH4808 100mgDrug: YH4808 200mgDrug: YH4808 100mg (repeat dose)Drug: YH4808 800mg (single dose)
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 134
- Registration Number
- NCT01007019
- Locations
- π°π·
Clinical trials center, Seoul national university hospital, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath